|
Co-Principal Investigator(s): Robin Shrestha-Kuwahara, MPH1,
Robert Horsburgh, MD2, Stefan Goldberg, MD1
Project Dates: 2005-2009
Project Overview: As one of the TB Epidemiologic Studies
Consortium (TBESC) research studies, this project aims to understand the scope
of treatment of latent tuberculosis infection (LTBI) in the United States and
Canada and to elucidate factors associated with acceptance and completion of
treatment. Phase 3 of the study is a prospective cohort study of approximately
2,400 adult patients 18 years and older who have been offered treatment for
LTBI in the United States and Canada. Twelve TBESC sites and associated local
clinics are participating in Phase 3. Taking an ecological approach, this study
addresses a wide range of factors, including knowledge, attitudes, and beliefs,
as well as toxicity, tolerability, social and economic factors, and issues
associated with clinic structures and the health care delivery system. The
interviews will be administered at the time treatment is offered and, for those
who initiate, again at the time participants drop out of or complete treatment.
A randomized sample of this cohort will receive brief, periodic follow-up
interviews at designated intervals. Enrollment will continue over a 12-month
period.
Objectives: The primary objectives of the study are to
identify potentially modifiable factors associated with acceptance or
nonacceptance of LTBI treatment, and to identify potentially modifiable factors
related to completion or noncompletion of treatment.
Target Audience: Persons offered treatment for LTBI in the
United States and Canada
Methods: Phase 3 will collect information through the
following methods and sources: 1) an initial interview administered to persons
offered treatment for LTBI to assess the factors affecting patients' decision
and ability to initiate and complete treatment and to identify potentially
modifiable factors related to acceptance and completion of treatment; 2) an
exit interview administered at the time of treatment cessation or completion;
3) follow-up interviews at periodic intervals for persons randomized to this
arm; 4) chart abstractions; and 5) a clinic survey to describe the local
context and LTBI treatment protocols.
Results: Project is in progress
Contact Information:
Robin Shrestha-Kuwahara, MPH
Behavioral Scientist
Centers for Disease Control and Prevention
Division of Tuberculosis Elimination
1600 Clifton Road, NE, Mailstop E-10
Atlanta, GA 30333
E-mail: rbk5@cdc.gov
Relative Content:
1 Division of Tuberculosis Elimination, Centers for Disease Control
and Prevention
2 Boston University
|